Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Keryx Biopharmaceuticals    KERX

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Keryx Biopharmaceuticals : Traders Favorite: Keryx Biopharmaceuticals, McDonald's Corporation, Merck & Co, Hertz Global Holdings

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/22/2013 | 08:05pm CET

NEW YORK, April 22, 2013 -Bestdarnpennystocks.com, one of the leaders in providing investment alerts on U.S. stocks are announcing Investment Highlights on Keryx Biopharmaceuticals, McDonald's Corporation, Merck & Co, Hertz Global Holdings.

Keryx Biopharmaceuticals (NASDAQ:KERX) shares gained 5.48% to $8.47. The company, on March 11, announced its results for the fourth quarter and year ended December 31, 2012. The net loss for the 4th quarter ended December 31, 2012 was $6.6 million, or $0.09 per share versus $8.4 million for quarter 2011, representing a decrease of $1.8 million and Net loss for the year ended December 31, 2012, was $22.7 million versus $28.1 million for the year ended December 31, 2011, representing a decrease in net loss of $5.4 million.

At December 31, 2012, the Company had cash, cash equivalents, interest receivable, and investment securities of $14.7 million, as compared to $39.5 million at December 31, 2011.

Has KERX Reached The Bottom and ready To Hit 52-week High? Find Out Here http://bestdarnpennystocks.com/landing-new/home-aw2.php?code=KERX (OR Just copy and paste the link)

McDonald's Corporation(NYSE:MCD) shares decreased 1.13% to $98.80. The company, on April 19, posted first-quarter profit that was little changed as same-store sales dropped in the U.S. for the first time since 2003 amid soft global demand. Net income was about $1.27 billion, or $1.26 share, compared with $1.27 billion, or $1.23, a year earlier. Analysts projected $1.26, the average of 29 estimates compiled by analyst.

Has MCD Reached The Bottom and ready To Hit 52-week High? Find Out Here http://bestdarnpennystocks.com/landing-new/home-aw2.php?code=MCD (OR Just copy and paste the link)

Additionally, MCD?s stock had its ?buy? rating restated by analysts at Janney Montgomery Scott in a research report issued to clients and investors on April 16. They currently have a $115.00 price target on the stock.

Merck & Co., Inc.(NYSE:MRK) shares fell 0.38% to $47.31. The company, on April 1st reported that it will hold its first-quarter 2013 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Wednesday, May 1.

Has MRK Reached The Bottom and ready To Hit 52-week High? Find Out Here http://bestdarnpennystocks.com/landing-new/home-aw2.php?code=MRK (OR Just copy and paste the link)

Additionally, the company, on April 10, announced that its New Drug Application for an investigational, tablet formulation of the company's antifungal agent, NOXAFIL (posaconazole), has been accepted for review by the U.S. Food and Drug Administration (FDA).

Hertz Global Holdings, Inc. (NYSE:HTZ) shares decreased 0.76% to $23.54. The company, on April 16, agreed to acquire a 20% stake in Beijing-based China Auto Rental Holdings Inc. to expand its presence in China's car-rental market. Financial terms weren't disclosed.

How Should Investors Trade HTZ Now? Get Free Trend Analysis Here http://bestdarnpennystocks.com/landing-new/home-aw2.php?code=HTZ (OR Just copy and paste the link)

Additionally, the company, on April 8, announced that its wholly-owned subsidiary, The Hertz Corporation ("Hertz"), has successfully completed a repricing of its currently outstanding $1,372 billion senior secured tranche B term loan facility. As part of the repricing, the tranche B term loans will be replaced by new tranche B-2 term loans.

About bestdarnpennystocks.com
bestdarnpennystocks.com?s team is engaged in providing stock newsletters on various hot penny stocks on a regular basis. Our instant stock news on Major Gainers, small cap penny stocks and various other stocks, guides investors in making the wise stock market investments decision. In order to get update to the markets, we would advise you sign up to our free newsletters. You can become leader in stock market by keeping track of the daily activity.

Disclaimer
The assembled information disseminated by bestdarnpennystocks.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. bestdarnpennystocks.com does expect that investors will buy and sell securities based on information assembled and presented in bestdarnpennystocks.com. PLEASE always do your own due diligence, and consult your financial advisor.
Contacts:
bestdarnpennystocks.com
1419 Westwood Blvd Los Angeles, CA
90024-4911
[email protected]


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on KERYX BIOPHARMACEUTICALS
11/14 KERYX BIOPHARMACEUTICALS : to Webcast its Presentations at Investor Healthcare C..
11/13 KERYX BIOPHARMACEUTICALS : Today’s Research Reports on Trending Tickers: Keryx B..
11/13 KERYX BIOPHARMACEUTICALS : U.S. FDA Approves Auryxia Tablets as a Treatment for ..
11/09 KERYX BIOPHARMACEUTICALS : to Webcast its Presentations at Investor Healthcare C..
11/09 KERYX BIOPHARMACEUTICALS : FDA Approval For Expanded Indication To Move The Need..
11/09 KERYX BIOPHARMACEUTICALS : Corporate News Blog – Keryx Announces FDA Approval of..
11/09 KERYX BIOPHARMACEUTICALS : Announces Presentation of Real World Dialysis Data of..
11/08 Keryx Biopharmaceuticals to Webcast its Presentations at Investor Healthcare ..
11/08 KERYX BIOPHARMACEUTICALS : U.S. FDA Approves Auryxia (ferric citrate) Tablets as..
11/07 KERYX BIOPHARMACEUTICALS : Biopharma reports 3Q loss
More news
News from SeekingAlpha
11/22 Tracking David Abrams' Abrams Capital Management Portfolio - Q3 2017 Update
11/17 KERYX : The Solution Is The Problem
11/14 Tracking Seth Klarman's Baupost Group Holdings - Q3 2017 Update
11/09 YOUR DAILY PHARMA SCOOP : Valeant Remains Risky, Novartis's Kisqali, Tesaro Tumb..
11/09 YOUR DAILY PHARMA SCOOP : Portola Upside, Novartis Reports Positive Cosentyx Dat..
Financials ($)
Sales 2017 60,0 M
EBIT 2017 -85,9 M
Net income 2017 -150 M
Finance 2017 22,4 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 9,27x
EV / Sales 2018 4,44x
Capitalization 578 M
Chart KERYX BIOPHARMACEUTICALS
Duration : Period :
Keryx Biopharmaceuticals Technical Analysis Chart | KERX | US4925151015 | 4-Traders
Technical analysis trends KERYX BIOPHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 7,14 $
Spread / Average Target 47%
EPS Revisions
Managers
NameTitle
Gregory P. Madison President, Chief Executive Officer & Director
Michael W. Rogers Chairman
Christine A. Carberry Chief Operating Officer & Senior Vice President
Scott A. Holmes Chief Financial Officer & Senior Vice President
John F. Neylan Chief Medical Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
KERYX BIOPHARMACEUTICALS-16.89%578
GILEAD SCIENCES1.16%94 693
REGENERON PHARMACEUTICALS6.67%41 304
VERTEX PHARMACEUTICALS100.10%36 699
GENMAB4.43%11 899
EXELIXIS, INC.76.93%7 707